Molecular glue degraders: Lilly, AbbVie sign billion-dollar deals; BMS leads with three late-stage drugs

Data Compilation
#PharmaFlow

Pipeline Prospector Feb 2025: Bain buys Mitsubishi Tanabe for US$ 3.4 bn; Japan’s Ono gets FDA nod for rare joint tumor drug

Stock Recap
#PipelineProspector

ISD

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

26 API Suppliers, 15 USDMF, 3 CEP/COS, 5 JDMF, 7 KDMF, 3 NDC API, 8 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

115 FDF Dossiers, 65 FDA Orange Book, 21 Europe, 4 Canada, 2 Australia, 13 South Africa, 10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 40MG, TABLET;ORAL - 5MG, CAPSULE, EXTENDED RELEASE;ORAL - 40MG, TABLET;ORAL - 37.5MG;20MG

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 9 DKSH, 3 Faran Shimi Pharmaceutical, 4 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 ACG Worldwide, 6 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 13 BASF, 11 Corel Pharma Chem, 6 DFE Pharma, 1 Finar, 9 Gangwal Chemicals, 5 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 36 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 13 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 3 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 19 Roquette, 13 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 3 The Dow Chemical Company, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

63 Fillers, Diluents & Binders, 47 Coating Systems & Additives, 28 Thickeners and Stabilizers, 26 Controlled & Modified Release, 22 Direct Compression, 19 Granulation, 17 Disintegrants & Superdisintegrants, 16 Lubricants & Glidants, 15 Solubilizers, 13 Film Formers & Plasticizers, 12 Co-Processed Excipients, 11 Topical, 10 Taste Masking, 9 Empty Capsules, 7 Emulsifying Agents, 7 Parenteral, 6 Chewable & Orodispersible Aids, 5 Rheology Modifiers, 5 API Stability Enhancers, 4 Vegetarian Capsules, 4 Coloring Agents, 2 Surfactant & Foaming Agents

DIGITAL CONTENT

9 News #PharmaBuzz

9 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 32 Regulatory FDF Prices

MARKET PLACE

11 APIs, 4 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Certificate Holder	Certificate No.	Substance	Issue Date	Status	Type	End Date	Substance No.
28/03/2025	Dipharma	Italy	DIPHARMA FRANCIS S.R.L. Baranzate IT	R1-CEP 2013-295 - Rev 00	Isosorbide dinitrate, diluted, 25% in lactose monohydrate	2022-02-09	Valid	Chemical		1117
28/03/2025	Dipharma	Italy	DIPHARMA FRANCIS S.R.L. Baranzate IT	R1-CEP 2013-298 - Rev 00	Isosorbide dinitrate, diluted, 40% in lactose monohydrate	2022-02-09	Valid	Chemical		1117

ISD

ISD

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

26 API Suppliers

15 USDMF

3 CEP/COS

5 JDMF

7 KDMF

3 NDC API

8 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

FINISHED DOSAGE FORMULATIONS

115 FDF Dossiers

65 FDA Orange Book

21 Europe

4 Canada

2 Australia

13 South Africa

10 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 30MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 40MG

TABLET;ORAL - 5MG

CAPSULE, EXTENDED RELEASE;ORAL - 40MG

TABLET;ORAL - 37.5MG;20MG

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

9 DKSH

3 Faran Shimi Pharmaceutical

4 Gangwal Healthcare

2 Nanjing Well Pharmaceutical

1 Pfanstiehl

4 ACG Worldwide

6 Actylis

1 Aeon Procare

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

13 BASF

11 Corel Pharma Chem

6 DFE Pharma

1 Finar

9 Gangwal Chemicals

5 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

36 Kerry

4 Kima Chemical

6 Lonza Capsugel

13 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

1 Novo Excipients

2 Pharmatrans-Sanaq

3 Pluviaendo

3 Prachin Chemical

1 Qianhao Chemical (Hebei) Co., Ltd

2 Qualicaps

19 Roquette

13 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

11 Sigachi Industries

3 The Dow Chemical Company

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

63 Fillers, Diluents & Binders

47 Coating Systems & Additives

28 Thickeners and Stabilizers

26 Controlled & Modified Release

22 Direct Compression

19 Granulation

17 Disintegrants & Superdisintegrants

16 Lubricants & Glidants

15 Solubilizers

13 Film Formers & Plasticizers

TABLET;ORAL - 10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 20MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons